Released May 16, 2022, after the close
10-Q filed May 16, 2022, 46 days after period end · 0000950170-22-010064
Q1 2022 · 10-Q
Revenue$247.00K$247.00K −96.6% vs Q1 2021no prior Q4 2021 on file
Net Income-$32.80M-$32.80M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$1.01-$1.01 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$30,207,000N/M
Operating Cash Flow-$28,223,000N/M
Margins · derived
Operating margin-12229.6%−11963.8 pt vs Q1 2021
Net margin-13279.4%−13013.6 pt vs Q1 2021
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $247.00K | $7.30M | $169.00K | $3.81M |
| Net Income | -$32.80M | -$19.40M | -$23.30M | -$5.10M |
| EPS Diluted | -$1.01 | -$0.66 | -$1.22 | -$0.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR